Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models

被引：0
|
作者：
Caterina Peraldo-Neia
Giuliana Cavalloni
Marco Soster
Loretta Gammaitoni
Serena Marchiò
Francesco Sassi
Livio Trusolino
Andrea Bertotti
Enzo Medico
Lorenzo Capussotti
Massimo Aglietta
Francesco Leone
机构：
[1] IRCCS-Candiolo,University of Turin Medical School, Department of Oncology
[2] IRCCS-Candiolo,Fondazione del Piemonte per l’Oncologia (FPO)
[3] IRCCS-Candiolo,Laboratory of Tumor Microenvironment
[4] Unit of Molecular Pharmacology,University of Turin Medical School
[5] IRCCS-Candiolo,Laboratory of Oncogenomics
[6] IRCCS-Candiolo,Department of General Surgery and Surgical Oncology
[7] Italy,undefined
[8] Ospedale Mauriziano Umberto I,undefined
来源：
BMC Cancer | / 14卷
关键词：
Biliary tract carcinoma; ET-743; Preclinical model; Chemotherapy; Patient-derived xenograft;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 39 条
  • [1] Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
    Peraldo-Neia, Caterina
    Cavalloni, Giuliana
    Soster, Marco
    Gammaitoni, Loretta
    Marchio, Serena
    Sassi, Francesco
    Trusolino, Livio
    Bertotti, Andrea
    Medico, Enzo
    Capussotti, Lorenzo
    Aglietta, Massimo
    Leone, Francesco
    BMC CANCER, 2014, 14
  • [2] Preclinical evidence of ET-743 as a potential chemotherapy option for the treatment of biliary carcinoma
    Leone, Francesco
    Peraldo-Neia, Caterina
    Cavalloni, Giuliana
    Soster, Marco
    Gammaitoni, Loretta
    Marchia, Serena
    Agiietta, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [3] In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug
    Esther F. A. Brandon
    Rolf W. Sparidans
    Kees-Jan Guijt
    Sjoerd Löwenthal
    Irma Meijerman
    Jos H. Beijnen
    Jan H. M. Schellens
    Investigational New Drugs, 2006, 24 : 3 - 14
  • [4] In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug
    Brandon, EFA
    Sparidans, RW
    Guijt, KJ
    Löwenthal, S
    Meijerman, I
    Beijnen, JH
    Schellens, JHM
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (01) : 3 - 14
  • [5] Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells
    Harika Atmaca
    Selim Uzunoglu
    European Cytokine Network, 2014, 25 : 1 - 7
  • [6] Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells
    Atmaca, Harika
    Uzunoglu, Selim
    EUROPEAN CYTOKINE NETWORK, 2014, 25 (01) : 1 - 7
  • [7] POTENT ANTI-CANCER EFFECT OF CROCIN AGAINST HEPATOCELLULAR CARCINOMA: A PRECLINICAL STUDY
    Amin, A.
    Daoud, S.
    Schneider-Stock, R.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S423 - S423
  • [8] Potent anti-cancer effect of crocin against hepatocellular carcinoma: A preclinical study
    Amin, Amr
    Schneider-Stock, Regine
    Daoud, Sayel
    CANCER RESEARCH, 2012, 72
  • [9] Anti-Cancer Effect of Quercetin in Xenograft Models with EBV-Associated Human Gastric Carcinoma
    Lee, Hwan Hee
    Lee, Seulki
    Shin, Yu Su
    Cho, Miyeon
    Kang, Hyojeung
    Cho, Hyosun
    MOLECULES, 2016, 21 (10)
  • [10] Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models
    Chen, Ping
    Stone, Jennifer
    Sullivan, Garrett
    Drisko, Jeanne A.
    Chen, Qi
    FREE RADICAL BIOLOGY AND MEDICINE, 2011, 51 (03) : 681 - 687
1234